Core Viewpoint - LUPENG Pharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1] Company Overview - LUPENG Pharmaceutical is a leading global biopharmaceutical company with a proprietary BeyondX oral drug chemistry platform, focusing on the design, discovery, clinical development, and commercialization of high bioavailability oral drugs to meet unmet medical needs in cancer and autoimmune disease patients [5] Key Product Information - The company's core product, LP-168, is a dual BTK inhibitor in the NDA stage, recognized as the world's first and only "covalent and non-covalent" dual BTK inhibitor, showing best-in-class potential in oncology and autoimmune disease fields [5] - LP-168 can eliminate both wild-type and resistant mutant BTK tumor cells, overcoming resistance limitations seen in traditional BTK inhibitors [5] - The product has demonstrated significant clinical benefits and excellent safety, with a lower incidence of treatment-related adverse events compared to previous BTK inhibitors [5] Market Potential - LP-168 has strategically extended its application to autoimmune indications, targeting major autoimmune diseases such as ITP, pMN, MS, and gMG, capturing significant value in the rapidly growing autoimmune treatment market [6] - The global BTK inhibitor market is projected to grow from $12 billion in 2024 to $25.1 billion by 2035, with a compound annual growth rate (CAGR) of 6.8% from 2025 to 2035 [6] Financial Performance - The company reported losses of RMB 159.4 million and RMB 3.4 million for the years 2023 and 2024, respectively [7] - For the six months ending June 30, 2024, and June 30, 2025, the company recorded profits of RMB 32.9 million and RMB 35.9 million, respectively [7]
新股消息 | 麓鹏制药递表港交所 核心产品LP-168为全球首个且唯一的“共价兼非共价”双重BTK抑制剂
智通财经网·2025-11-02 02:53